Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DTRA Awards $3.3 M Contract to Psioxus Therapeutics

Published: Friday, January 18, 2013
Last Updated: Friday, January 18, 2013
Bookmark and Share
PsiOxus Therapeutics, Ltd. has been awarded a $3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants.

PsiOxus will use the company’s proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates: the recombinant Protective Antigen (rPA) for Anthrax and the Venezuelan Equine Encephalopathy Virus (VEEV). PolyMAP is an immunotherapeutic platform that combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.

“We are honoured to have received this contract from the DTRA and excited at the prospect of helping to improve the safety and efficacy of these two very important vaccine candidates using the PolyMAP technology,” said Dr. John Beadle, CEO of PsiOxus Therapeutics. “Adjuvant platforms are key to innovating and growing the global vaccine market, and we are confident that our immunotherapeutic platform PolyMAP, along with our oncolytic vaccines expertise and team of renowned scientists, will play a significant and long-term role in the future of the industry.”

The contract will support work over a three-year period in the US, as well as in the company’s new state-of-the-art laboratory in Oxford, which has been designed and equipped as a category two laboratory for the handling of live viruses. 

The global market for Human Vaccines is forecast to reach US$32.21 billion by the year 2017 1, with key factors such as the growing pediatric population, world travel, and addiction driving market growth. The potential for significant growth and uptake of therapeutic vaccines is expected to further add to this significant growth potential in the longer term.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PsiOxus to Release Study Results of Oncolytic Vaccine Enadenotucirev
Phase I studies to be presented at 2014 ASCO annual meeting.
Saturday, May 17, 2014
Myotec Merges with Hybrid Biosystems to Form PsiOxus Therapeutics
Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces the merger of its portfolio company Myotec Therapeutics Ltd. (Myotec) with Hybrid Biosystems Ltd. (Hybrid) to form PsiOxus Therapeutics.
Wednesday, December 15, 2010
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!